8-K current report · filed Nov 3, 2026

Guardant Health, Inc. (GH) 8-K Current Report: November 3, 2026

Item 5.02GH overview

Short answer

Guardant Health, Inc. (GH) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Retention signal: founders and Co-CEOs Helmy Eltoukhy and AmirAli Talasaz each received 465,413 target PSUs.

Guardant Health, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Retention signal: founders and Co-CEOs Helmy Eltoukhy and AmirAli Talasaz each received 465,413 target PSUs
  • 100% performance-based awards tied to relative TSR versus S&P 500 over three-year and five-year periods
  • 25% of PSUs use the three-year period ending May 31, 2029; 75% use the five-year period ending May 31, 2031
  • Payout ranges from 0% below the 40th percentile to 250% at or above the 90th percentile
  • One-year and six-month post-vesting holding requirements reinforce long-term alignment, while awards support executive retention and succession continuity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Guardant Health, Inc. 8-K filings

Get the next GH 8-K as it lands

Follow GH for push alerts, or ask the research agent what this filing means.